Carregant...
Role of Direct Oral Anticoagulants in Patients with Kidney Disease
The anticoagulation field is experiencing a renaissance that began with regulatory approval of the direct thrombin inhibitor, dabigatran, a Direct Oral Anticoagulant (DOAC) in 2010. The DOAC medication class has rapidly evolved to include the additional approval of four direct factor Xa inhibitors....
Guardat en:
| Publicat a: | Kidney Int |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7093256/ https://ncbi.nlm.nih.gov/pubmed/32107019 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.kint.2019.11.027 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|